

# News Releases

All Years



Search

GO

[Advanced Search](#)

**May 8, 2019**

## **Portola Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update**

**– First Quarter Revenues of \$22.2 Million; Andexxa® Product Revenues Grow 45% to \$20.3 Million –**

SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three months ended March 31, 2019 and...

**Apr 26, 2019**

## **European Commission Grants Conditional Marketing Authorization for Portola Pharmaceuticals' Ondexxa™ (andexanet alfa), the First and Only Antidote for the Reversal of Factor Xa Inhibitors**

**– Major Advance in the Treatment of European Factor Xa Inhibitor Patients Hospitalized with Life-Threatening Bleeding –**

SOUTH SAN FRANCISCO, Calif., April 26, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the European Commission (EC) has granted conditional Marketing...

**Apr 24, 2019**

## **Portola Pharmaceuticals Announces Retirement of Dr. John Curnutte, Executive Vice President and Head of Research and Development**

SOUTH SAN FRANCISCO, Calif., April 24, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that John Curnutte, M.D., Ph.D., Executive Vice President and Head of...

**Apr 17, 2019**

## **Portola Pharmaceuticals to Announce First Quarter 2019 Financial Results on Wednesday, May 8, 2019**

SOUTH SAN FRANCISCO, Calif., April 17, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that it will host a webcast and conference call to discuss the Company'

**Mar 20, 2019**

## **Portola Pharmaceuticals' Co-Founder Dr. Charles Homcy Retires from the Company's Board of Directors**

SOUTH SAN FRANCISCO, Calif., March 20, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that on March 15, 2019 Charles Homcy, M.D., informed the Board of his...

**Mar 6, 2019**

## **Portola Pharmaceuticals to Webcast Presentation at Cowen and Company's 39th Annual Health Care Conference**

SOUTH SAN FRANCISCO, Calif., March 06, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that Scott Garland, Portola's president and chief executive...

**Mar 1, 2019**

## **European CHMP Adopts Positive Opinion on Ondexxa™ (andexanet alfa) Portola Pharmaceuticals' Factor Xa Inhibitor Reversal Agent**

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...

**Mar 1, 2019**

## **Portola Pharmaceuticals Enters into \$125 Million Loan Agreement with HealthCare Royalty Partners and Athyrium Capital Management**

**Agreement Provides Financial Flexibility for the Ongoing Commercialization of Andexxa® and Launch Preparations in Europe**

SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced that it has entered into a \$125 million loan agreement with...

**Mar 1, 2019**

## **Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update**

**– Fourth Quarter Andexxa® Revenues of \$14.0 Million; Third Consecutive Quarter of Strong Revenues –**


SOUTH SAN FRANCISCO, Calif., March 01, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today reported financial results for the three and twelve months ended December 31,...

**Feb 7, 2019**

## **Portola Pharmaceuticals Announces Full Results from the ANNEXA-4 Study of the Factor Xa Inhibitor Reversal Agent Andexxa® in Patients with Life-Threatening Bleeding**

**– Excellent or Good Hemostasis Achieved in 82 Percent of Evaluable Patients –**

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA) today announced full results from ANNEXA-4, the Company's Phase 3b/4 trial of its...

Show 10  per page

 [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) ... [27](#) 



---

<https://investors.portola.com/news-releases?l=10&o=40>